Michael J. Fox Foundation for Parkinson's Research
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Michael J. Fox Foundation for Parkinson's Research
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
Private Company Edition: Forbion closed two funds totaling €1.35bn ($1.5bn) and Glide Healthcare raised €600m ($657.5m) for its latest fund, joining recent venture capital raises by Lux Capital and Wellington Management, but in the first quarter biopharma VC company financings fell dramatically.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.